The Board of Directors of Eurocine Vaccines has resolved to request scientific advice from the Swedish Medical Products Agency ahead of submitting the clinical trial application with the company’s vaccine candidate against chlamydia. The scientific advice aims to strengthen Eurocine Vaccines´ documentation and maximize the probability of a swift approval of the application. As a consequence, Eurocine Vaccines plans to initiate the clinical study in the first half-year 2023.
Prior to the clinical study with the vaccine candidate against chlamydia, a scientific advice will be carried out with the Swedish Medical Products Agency. This was resolved by the Board of Directors of Eurocine Vaccines today. To have all relevant data from the ongoing development available in connection with the advice, the start of the clinical study is now planned for the first half of 2023, which is a postponement compared to the previous plan which stated the autumn of 2022.
This information is such information that Eurocine Vaccines AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 21 December 2021.